MarketsandMarkets Conferences, Author at Blogs & Articles

Industrial Automation Companies of 2019

August 9, 2019August 9, 2019 MarketsandMarkets Conferences

Industrial automation is a process of using various control devices like PC’s/PLC’s/DCS to have control on various operations of an industry with significantly lesser human intervention that can provide automatic control performance. Industrial automation can be achieved by using technologies that can get desired performance or output with high productivity, quality and flexibility with less safety issues. Advantages of Industrial Automation High productivity High Quality High flexibility High Information Accuracy High safety Here’s a list of companies who are leading the industrial automation market: ABB A Switzerland based multinational company…

Speaker Interview With Stefan Glueck For 2ND Annual MarketsandMarkets Next Gen Immuno-Oncology Congress

July 31, 2019 MarketsandMarkets Conferences

Philadelphia, USA July 31, 2019 – MarketsandMarkets recently interviewed Stefan Glueck, Senior Vice President, Global Medical Affairs, Celgene regarding the 2nd Annual MarketsandMarkets Next Gen Immuno-Oncology Congress, taking place on September 19 – 20, 2019 at Hilton Garden Inn Philadelphia Center City. Q. What are the recent advances in the immune-oncology and current challenges that need immediate attention? A. advances: more indication using ICI and combinations with chemo, and other IO. even brain metastases seem to respond to smart combinations. challenges: primary and secondary resistance and still less than 50% of patients even in…

Speaker Interview With Frank Borriello For 2nd Annual MarketsandMarkets Next Gen Immuno-Oncology Congress

July 31, 2019 MarketsandMarkets Conferences

Philadelphia, USA July 31, 2019 – MarketsandMarkets recently interviewed Frank Borriello, CEO, Alloplex Biotherapeutics, regarding the 2nd Annual MarketsandMarkets Next Gen Immuno-Oncology Congress, taking place on September 19 – 20, 2019 at Hilton Garden Inn Philadelphia Center City. Q. What are the recent advances in the immune-oncology and current challenges that need immediate attention? A. While there have been many advances in the field of cellular therapy in oncology, the common element limiting their adoption will be reproducibility of manufacturing, whether autologous or allogeneic, as well as generalizability across multiple tumor types, whether…

Speaker Interview With Alfred Budillon FOR 4th Annual MarketsandMarkets Epigenetics Congress

July 30, 2019August 6, 2019 MarketsandMarkets Conferences

London, UK July 30, 2019 – MarketsandMarkets recently interviewed Alfred Budillon, Chief Experimental Pharmacology Unit Department, Istituto Nazionale Tumori, Italy regarding the 4th Annual MarketsandMarkets Epigenetics Congress, taking place on 3-4 October 2019 at Radisson Blu Edwardian, Grafton, London, UK. Dr. Budillon graduated in Medicine and passed the Specialty Certification in Oncology at University Federico II, Naples, Italy. He obtained the PhD in Oncology from University G. D’Annunzio of Chieti, Italy, and a master’s degree in health economy, Management and Bioethics. Dr. Budillon is currently the chief of Experimental Pharmacology, National Cancer Institute…

Speaker Interview With Gavin Reynolds For 4TH Annual MarketsandMarkets Epigenetics Congress

July 29, 2019 MarketsandMarkets Conferences

London, UK July 29, 2019 – MarketsandMarkets recently interviewed Gavin Reynolds, Professor Emeritus, Queen’s University Belfast, UK regarding the 4th Annual MarketsandMarkets Epigenetics Congress, taking place on 3-4 October 2019 at Radisson Blu Edwardian, Grafton, London, UK. Gavin Reynolds is Honorary Professor at Sheffield Hallam University and Professor Emeritus, previously Chair of Neuroscience, at Queen’s University Belfast. His main research interests lie in two directions: the neurotransmitter pathology of schizophrenia, and the mechanisms underlying the beneficial and adverse effects of antipsychotics and other psychoactive drugs, with a recent focus on pharmacogenetic and…

Gene Therapy for Spinal Muscular Atrophy approved by FDA

July 26, 2019 MarketsandMarkets Conferences

A new treatment for a rare childhood disorder which cost $2.125 million for a single dose, one of the most expensive medicine available is approved by The US Food and Drug Administration. Spinal Muscular Atrophy, a condition driven by defects in the SMN1 gene causing burdened babies lose muscle control, the medicine is designed to treat the disease. In the US each year about 400 babies is being affected by the illness and kills those with the most common type of the disease in a couple of years. The gene…

Speaker Interview with Silvia Cainarca for the 5th Annual Neuroscience R&D Technologies Conference

July 24, 2019July 24, 2019 MarketsandMarkets Conferences

London, UK July 24, 2019 – MarketsandMarkets recently interviewed Dr. Silvia Cainarca, Principal Investigator, iPSC Lab iTools & Solutions regarding the 5th Annual Neuroscience R&D Technologies Conference, taking place on 3-4 October 2019 at Radisson Blu Edwardian, Grafton, London, UK. Q. What are the recent advances in Neuroscience R&D Technologies for Neurodegenerative disorders and current challenges that need immediate attention? A. Even if many powerful experimental animal models were set up in these years that can recapitulate the hallmark characteristics of different neuropathic diseases, one of the main challenges in their applicability…

Speaker Interview with Lorenzo Pasquali for 4th Annual MarketsandMarkets Epigenetics Congress

July 23, 2019July 23, 2019 MarketsandMarkets Conferences

London, UK July 23, 2019 – MarketsandMarkets recently interviewed Lorenzo Pasquali, Group Leader, Endocrine Regulatory Genomics Laboratory IGTP, Spain regarding the 4th Annual MarketsandMarkets Epigenetics Congress, taking place on 3-4 October 2019 at Radisson Blu Edwardian, Grafton, London, UK. Dr. Lorenzo Pasquali is Group Leader of the Endocrine Regulatory Genomics laboratory at IGTP, Barcelona, Spain . His studies helped to map the epigenetic landscape of the insulin producing pancreatic islet cells resulting in milestone publications that opened the path to understand genomic regulation of the islets of Langerhans and shed…

AveXis Directs to Catalent’s Paragon for Extra Gene Therapy Producing Capacity

July 19, 2019July 19, 2019 MarketsandMarkets Conferences

Catalent has approved AveXis that, a Novartis Company to use its brand-new commercial manufacturing center near Baltimore-Washington International Airport as an extra site production site for its spinal muscular atrophy (SMA) gene therapy Zolgensma® (onasemnogene abeparvovec-xioi). A collaboration contract was signed by Catalent and AveXis to ensure long term strategic agreement but has not been disclosed yet. AveXis will use the dedicated production space within Paragon’s Harmans, MD, facility, a 151,000-square-foot old warehouse that Paragon changed into a contract developing and a manufacturing site which opened in April. Andy Stober,…

Genmab Partners Raised $503M U.S. IPO on Cancer Antibodies with BliNK Biomedical

July 19, 2019July 19, 2019 MarketsandMarkets Conferences

Genmab through collaboration with Blink biomedicals raised a whopping $503 Million through an American initial public offering (IPO) all this got revealed on Friday during an event. Genmab also launched an up to $200 million-per-product cancer therapy with Blink biomedicals. Blink biomedicals got a license approved by Genmab exclusively for antibodies targeting CD47, which Genmab plans to combine with its duo body platform technology to produce new bispecific antibodies for fighting cancer. Genmab CEO Jan van de Winkel, Ph.D. gave his words about this CD47 stating that “CD47 has shown…